R230C and C230C Variants of ABCA1 and Glyburide Response

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran85 enrolled

Overview

The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes.

Specific objectives: 1. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables: * Fasting glucose * Percentage reduction * Hemoglobin A1c, * Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol * Weight 2. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables: * Number of cases that reach fasting plasma glucose lower than 110 mg/dl * Number of cases that reach an HbA1c less than 7%

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Type 2 Diabetes

Interventions

GlyburideDRUG

Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table: Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults 20 to 79 years * Body mass index \>18 and 39.9 ≤ * Men or women * Mexicans mestizos. * Moderate hyperglycemia (126 to 250 mg/dl and HbA1c levels between 7 and 10%) despite being treated with a dietary program in combination or not with metformin (2 g/d). Exclusion Criteria: * Patients with chronic complications of diabetes: ischemic heart disease, stroke, proliferative retinopathy or blindness, albuminuria, chronic diarrhea, gastroparesis, non-traumatic amputation of lower limbs. * Patients with any monogenic syndrome, obesity, diabetes or hypoalphalipoproteinemia * Patients with acquired diseases that produce secondarily obesity or diabetes. * Treatment with anorexigenics or accelerate weight loss at the time of the selection. * Cardiovascular event in the 6 months prior to study entry. * Steroids, chemotherapy, immunosuppressive or radiotherapy. * Infections or concurrent acute diseases. * Catabolic diseases such as cancer or AIDS * Pregnancy

Locations (1)

Instituto Nacional de Ciencias Medicas y Nutricion

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Change in plasma fasting glucose

The effects of the alleles under study on the glucose lowering effect of glyburide will be assessed in 20 week study. Diet and exercise will be controlled per protocol

Time frame: 20 weeks

Secondary Outcomes

HbA1c levels

Time frame: 20 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.